GSK shares fell sharply after disappointing vaccine sales raised investor concerns over slowing demand for flagship treatments and intensifying sector competition.

GSK projects its oncology pipeline will nearly double next year, riding a wave of targeted acquisitions aimed at countering upcoming patent expirations.